Gary Titus

2018

In 2018, Gary Titus earned a total compensation of $3.5M as Former Chief Financial Officer at UroGen Pharma Ltd., a 224% increase compared to previous year.

Compensation breakdown

Option Awards$695,835
Salary$175,000
Other$2,616,274
Total$3,487,109

Titus received $2.6M in other compensation, accounting for 75% of the total pay in 2018.

Titus also received $695.8K in option awards and $175K in salary.

Rankings

In 2018, Gary Titus' compensation ranked 3,260th out of 14,244 executives tracked by ExecPay. In other words, Titus earned more than 77.1% of executives.

ClassificationRankingPercentile
All
3,260
out of 14,244
77th
Division
Manufacturing
1,206
out of 5,765
79th
Major group
Chemicals And Allied Products
418
out of 2,128
80th
Industry group
Drugs
346
out of 1,817
81st
Industry
Pharmaceutical Preparations
265
out of 1,391
81st
Source: SEC filing on April 26, 2019.

Titus' colleagues

We found six more compensation records of executives who worked with Gary Titus at UroGen Pharma Ltd. in 2018.

2018

Ron Bentsur

UroGen Pharma Ltd.

Chief Executive Officer

2018

Stephen Mullennix

UroGen Pharma Ltd.

Chief Financial Officer

2018

Gil Hakim

UroGen Pharma Ltd.

Former President

2018

Peter Pfreundschuh

UroGen Pharma Ltd.

Chief Financial Officer

2018

Peter Pfreundschuh

UroGen Pharma Ltd.

Chief Financial Officer

2018

Mark Schoenberg

UroGen Pharma Ltd.

Chief Medical Officer

News

You may also like